Link to this page
Health Level Seven Reference Implementation Model, Version 3
Id | http://purl.bioontology.org/ontology/HL7/C1550465
http://purl.bioontology.org/ontology/HL7/C1550465
|
---|---|
Preferred Name | Intermediate |
Definitions |
<p>Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized\_Terminolo.htm) Projects: ISO 20776-1, ISO 20776-2</p><p>\[Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.\]</p><p>\[Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.\]</p><p>\[Note 3: This class also indicates a "buffer zone," to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.\]</p><p>\[Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).\]</p>
|
Type | http://www.w3.org/2002/07/owl#Class |
All Properties
definition | <p>Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized\_Terminolo.htm) Projects: ISO 20776-1, ISO 20776-2</p><p>\[Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.\]</p><p>\[Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.\]</p><p>\[Note 3: This class also indicates a "buffer zone," to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.\]</p><p>\[Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).\]</p> |
---|---|
prefLabel | Intermediate
|
notation | C1550465
|
HL7 code status | active
|
HL7PL | true
|
subClassOf | |
Semantic type UMLS property | |
HL7 internal Id | 10221
|
type | |
tui | T034
|
cui | C1550465
|
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |